Short-term hormone therapy with transdermal estradiol improves cognition for postmenopausal women with Alzheimer's disease: results of a randomized controlled trial.

摘要: We aimed to conduct a placebo-controlled, double-blind, parallel-group design intervention study evaluate the therapeutic efficacy of hormone therapy (HT) in postmenopausal women with mild moderate Alzheimer's disease (AD). The trial was designed dose-dependent effects transdermal 17-β estradiol, unopposed and opposed medroxyprogesterone (MPA, Provera©), for 12 months 43 AD. Participants were assessed using cognitive measures at baseline, 1, 3, 6, treatment eight weeks post (month 15). dropout rate 49% across months. As result Women's Health Initiative (WHI) anticipated increased attrition, protocol modified examine data only time points where attrition less than 30%. results sensitivity analyses indicated robust reliable collected first three trial. Data forty-three participants analyzed. HT had favorable multiple domains, including visual memory (p-values < 0.030) semantic 0.037) Moreover, treatment-related changes plasma estradiol positively correlated improvements memory. Short-term that includes use has on cognition